Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKCH | P24723 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.55 |
| ▸ | STK17B | O94768 | 1/20 | 0.55 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659614 | 0.89 | JAK2 (0.61) | PRKD3EGFRPRKCGPRKCBLCK | |
| Hydrochloric Acid SCHEMBL660445 | 0.88 | JAK2 (0.60) | PRKD3EGFRPRKCGPRKCBLCK | |
| SCHEMBL10246812 | 0.85 | CDK2 (0.58) | PRKD3EGFRPRKCGPRKCBLCK | |
| SCHEMBL14755163 | 0.85 | EGFR (0.54) | PRKD3EGFRPRKCGPRKCBLCK | |
| SCHEMBL10192761 | 0.83 | JAK2 (0.59) | PRKD3EGFRPRKCGPRKCBLCK | |
| SCHEMBL19847158 | 0.81 | PRKD3 (0.54) | PRKD3EGFRPRKCGPRKCBLCK | |
| SCHEMBL10245770 | 0.80 | JAK2 (0.62) | EGFRSTK17ACDK2JAK2ACVR1 | |
| SCHEMBL8239814 | 0.80 | PLK4 (0.68) | PRKD3STK17AMYLK4KCNH2CDK2 | |
| SCHEMBL10246683 | 0.79 | JAK2 (0.61) | EGFRSTK17ACDK2JAK2ACVR1 | |
| SCHEMBL10245501 | 0.78 | PRKD3 (0.57) | PRKD3EGFRPRKCGPRKCBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | AFRAXIS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | PRKD3 514/4885EGFR 3291/4885PRKCG 87/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | PRKD3 663/4885EGFR 3598/4885PRKCG 232/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | PRKD3 1170/4885EGFR 4263/4885PRKCG 230/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | PRKD3 455/4885EGFR 4252/4885PRKCG 547/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | PRKD3 632/4885EGFR 3833/4885PRKCG 144/4885 |
| US-20130225575-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS | SMN1; SMN2, PYGB, PMP22 | PRKD3 1475/4885EGFR 4745/4885PRKCG 207/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | PRKD3 433/4885EGFR 3863/4885PRKCG 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.